PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and Israel Expected to be Opened by End of Current Quarter Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage bio

Related Keywords

Israel ,United States ,Dikla Czaczkes Akselbrad ,Brian Ritchie ,Czaczkes Akselbrad ,Nasdaq ,Linkedin ,Exchange Commission ,European Journal Of Pharmaceutical Sciences ,Company Annual Report On Form ,Drug Administration ,Twitter ,Polypid Ltd ,Breached Agreement ,Abdominal Colorectal Surgical Site ,Late June ,Israel Expected ,Call Scheduled ,Corporate Highlights ,European Journal ,Chief Executive ,Call Dial In ,Webcast Information ,Polymer Lipid Encapsulation ,Active Pharmaceutical Ingredients ,Private Securities Litigation Reform Act ,Annual Report ,Polypid ,The Company ,